Simon Chiu

Simon Chiu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2013 in Journal of Complementary and Integrative Medicine
Verified
Journal Article
Closed access
SCSimon Chiu
Simon Chiu
KTKristen J. Terpstra
Kristen J. Terpstra
YBYves Bureau
Yves Bureau
JHJirui Hou
Jirui Hou
HRHana Raheb
Hana Raheb
MWMichael Woodbury-Farina
Michael Woodbury-Farina
Converging evidence suggests dysregulation of epigenetics in terms of histone-mediated acetylation/deacetylation imbalance in Parkinson's disease (PD). Targeting histone deacetylase (HDAC) in neuronal survival and neuroprotection may be beneficial in the treatment and prevention of neurodegenerative disorders. Few pharmacological studies use the transgenic model of PD to characterize the neuroprotection actions of a lead compound known to target HDAC in the brain. In our study, we investigated neuroprotective effects of liposomal-formulated curcumin: Lipocurc™ targeting HDAC inhibitor in the DJ-1(Park 7)-gene knockout rat model of PD. Group I (DJ-1-KO-Lipocurc™) received Lipocurc™ 20 mg/kg iv 3× weekly for 8 weeks; Group II: DJ-1 KO controls (DJ-1 KO-PBS) received i.v. phosphate-buffered saline (PBS). Group III: DJ-1-Wild Type (DJ-1 WT-PBS) received PBS. We monitored various components of motor behavior, rotarod, dyskinesia, and open-field behaviors, both at baseline and at regular intervals. Toward the end of the 8 weeks, we measured neuronal apoptosis and dopamine (DA) neuron-specific tyrosine hydroxylase levels by immunohistochemistry methods at post-mortem. We found that DJ-KO Group I and Group II, as compared with DJ-1 WT group, exhibited moderate degree of motor impairment on the rotarod test. Lipocurc™ treatment improved the motor behavior motor impairment to a greater extent than the PBS treatment. There was marked apoptosis in the DJ-1 WT group. Lipocurc™ significantly blocked neuronal apoptosis: the apoptotic index of DJ-1-KO-Lipocurc™ group was markedly reduced compared with the DJ-KO-PBS group (3.3 vs 25.0, p<0.001). We found preliminary evidence Lipocurc™ stimulated DA neurons in the substantia nigra. The ratio of immature to mature DA neurons in substantia nigra was statistically higher in the DJ-1-KO-Lipocurc™ group (p<0.025). We demonstrated for the first time Lipocurc™'s anti-apoptotic and neurotrophic effects in theDJ-1-KO rat model of PD. Our promising findings warrant randomized controlled trial of Lipocurc™ in translating the novel nanotechnology-based epigenetics-driven drug discovery platform toward efficacious therapeutics in PD.

1 January 2014 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SCSimon Chiu
Simon Chiu
NGNigel Gericke
Nigel Gericke
MFMichel Farina-Woodbury
Michel Farina-Woodbury
VBVladimir Badmaev
Vladimir Badmaev
HRHana Raheb
Hana Raheb
LGLiz Goble
Liz Goble
Introduction. Converging evidence suggests that PDE‐4 (phosphodiesterase subtype 4) plays a crucial role in regulating cognition via the PDE‐4‐cAMP cascade signaling involving phosphorylated cAMP response element binding protein (CREB). Objective. The primary endpoint was to examine the neurocognitive effects of extract Sceletium tortuosum (Zembrin) and to assess the safety and tolerability of Zembrin in cognitively healthy control subjects. Method. We chose the randomized double‐blind placebo‐controlled cross‐over design in our study. We randomized normal healthy subjects (total n = 21) to receive either 25 mg capsule Zembrin or placebo capsule once daily for 3 weeks, in a randomized placebo‐controlled 3‐week cross‐over design. We administered battery of neuropsychological tests: CNS Vital Signs and Hamilton depression rating scale (HAM‐D) at baseline and regular intervals and monitored side effects with treatment emergent adverse events scale. Results. 21 subjects (mean age: 54.6 years ± 6.0 yrs; male/female ratio: 9/12) entered the study. Zembrin at 25 mg daily dosage significantly improved cognitive set flexibility (P < 0.032) and executive function (P < 0.022), compared with the placebo group. Positive changes in mood and sleep were found. Zembrin was well tolerated. Conclusion. The promising cognitive enhancing effects of Zembrin likely implicate the PDE‐4‐cAMP‐CREB cascade, a novel drug target in the potential treatment of early Alzheimer’s dementia. This trial is registered with ClinicalTrials.gov NCT01805518.

1 December 2014 in Psychiatric Clinics of North America
Verified
Journal Article
Closed access
SCSimon Chiu
Simon Chiu
MWMichel A. Woodbury-Fariña
Michel A. Woodbury-Fariña
MSMujeeb U. Shad
Mujeeb U. Shad
MHMariwan Husni
Mariwan Husni
JCJohn Copen
John Copen
RCRobbie Campbell
Robbie Campbell

1 May 2017 in International Journal of Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SCSimon Chiu
Simon Chiu
Converging evidence suggests that Disrupted in Schizophrenia (DISC-1) is a recognized risk gene for schizophrenia. The interaction of DISC-with PDE-4 (Phosphodiesterase Subtype-4) plays a crucial role in neurodevelopment and neuro-inflammation in schizophrenia.. Serotonin has drawn increased attention for its role in modulating cognition function. Hence dual targeting Selective Serotonin Reuptake site (SSRI) and PDE-4 may offer novel therapeutic paradigm towards augmenting antipsychotics in schizophrenia. Translational studies show that the family of mesembrane-related alkaloids isolated from the South African plant: Sceletium tortuosum have been shown to hit dual targets: SSRI and PDE-4 allosteric site. The promising findings warrant a proof-of-concept randomized controlled study Zembrin extract in schizophrenia.

1 January 2017 in Journal of Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
SCSimon Chiu
Simon Chiu
MFMichel Woodbury Farina
Michel Woodbury Farina
KTKristen Terpstra
Kristen Terpstra
VBVladimir Badmaev
Vladimir Badmaev
ZCZack Cernovsky
Zack Cernovsky
CCChristina Chehade
Christina Chehade
Despite advances in pharmacotherapy, schizophrenia continues to carry a high societal disease burden related to positive and negative symptoms, and neurocognitive deficits and severe functional impairment. Findings from epigenetics have yet to translate the epigenetics targets to efficacious drug therapy. We review the repertoire of CNS pharmacology of curcumin derived from Curcuma Longa, commonly known as “turmeric”: the well-known curry extract. We highlight the body of evidence in support of the emerging role of curcumin as a panhistone deacetylase (HDAC) inhibitor regulating the expression of genes involved in inflammation and NMDA N-methyl-aspartic acid (NMDA)-glutamate systems, as related to schizophrenia. Based on the findings from translational studies of curcumin extracts, curcumin C-3 complex formulation (Supercurcumin™) and patented liposome-based curcumin (Lipocurc™), we propose that intravenous infusion of Lipocurc™ holds promise as the novel drug lead and preferred targeted brain delivery mode in reprogramming faculty epigenetics network and in remodeling restrictive chromatin configuration in schizophrenia. Phase II/Phase III epigenetics-biomarker-based randomized placebo-controlled trials in treatment resistant schizophrenia are warranted. Our approach of intravenous infusion of Lipocurc™ behaving as pan HDAC inhibitor represents a new paradigm of drug development in combining targeting epigenetics footprints with brain-specific drug delivery system in schizophrenia. Lipocurc™ can open the Pandora box in unexplored therapeutics vistas in modifying the phenotype of treatment resistant schizophrenia.

1 January 2017 in Journal of Systems and Integrative Neuroscience
Verified
Journal Article
Open access
SCSimon Chiu
Simon Chiu
AKAirudin Sulaiman Khan
Airudin Sulaiman Khan
VBVladimir Badmaev
Vladimir Badmaev
KTKristen Terpstra
Kristen Terpstra
ZCZack Cernovsky
Zack Cernovsky
CCChristina Chehade
Christina Chehade